<DOC>
	<DOCNO>NCT01016054</DOCNO>
	<brief_summary>This parallel arm study evaluate AGS-8M4 administered combination chemotherapy subject ovarian cancer . AGS-8M4 administer IV infusion disease worsens .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics AGS-8M4 Given Combination With Chemotherapy Women With Ovarian Cancer</brief_title>
	<detailed_description>All Subjects receive AGS-8M4 treatment . Subjects enrol 1 2 treatment arm accord disease status . A disease assessment perform every 8 9 week ( ± 3 day ) depend treatment arm assignment . The assessment base change clinical symptom , radiographic image . Subjects without evidence disease progression may continue receive treatment base original treatment assignment disease progression intolerability . A safety follow-up visit occur 4 week last dose infusion AGS-8M4 .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Ovarian Diseases</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Subjects recurrent disease Stage III/IV diagnosis epithelial ovarian cancer , fallopian tube cancer , primary peritoneal carcinoma Subjects either platinum resistant platinum sensitive ovarian cancer At least 14 day previous cytotoxic chemotherapy recover toxicity Left ventricular ejection fraction ( LVEF ) equal great institutional low limit normal measure echocardiogram MUGA ( ONLY require platinum resistant patient ) Active infection require treatment systemic ( intravenous oral ) antiinfectives ( antibiotic , antifungal , antiviral agent ) within 72 hour screen Use investigational drug within 30 day prior screen Prior monoclonal antibody therapy Avastin Avastin administration within 90 day screen History thromboembolic event bleed disorder ≤ 3 month ( e.g. , DVT PE )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Clinical Trial , Phase1</keyword>
	<keyword>Combination Drug Therapy</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety</keyword>
	<keyword>Ovarian</keyword>
</DOC>